David T Dexter
Overview
Explore the profile of David T Dexter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2873
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stephenson D, Alexander R, Aggarwal V, Badawy R, Bain L, Bhatnagar R, et al.
Digit Biomark
. 2021 Jan;
4(Suppl 1):28-49.
PMID: 33442579
Innovative tools are urgently needed to accelerate the evaluation and subsequent approval of novel treatments that may slow, halt, or reverse the relentless progression of Parkinson disease (PD). Therapies that...
12.
Martin-Bastida A, Tilley B, Bansal S, Gentleman S, Dexter D, Ward R
J Neural Transm (Vienna)
. 2020 Oct;
128(1):15-25.
PMID: 33079260
In these present studies, in vivo and and post-mortem studies have investigated the association between iron and inflammation. Early-stage Parkinson's disease (PD) patients, of less than 5 years disease duration,...
13.
Barker R, Bjorklund A, Gash D, Whone A, Van Laar A, Kordower J, et al.
J Parkinsons Dis
. 2020 Jun;
10(3):875-891.
PMID: 32508331
The concept of repairing the brain with growth factors has been pursued for many years in a variety of neurodegenerative diseases including primarily Parkinson's disease (PD) using glial cell line-derived...
14.
Lewis F, Fairooz S, Elson J, Hubscher-Bruder V, Brandel J, Soundararajan M, et al.
Arch Toxicol
. 2020 Feb;
94(3):813-831.
PMID: 32078022
Ubiquitin proteasome system (UPS) impairment, excessive cellular oxidative stress, and iron dyshomeostasis are key to substantia nigra dopaminergic neuronal degeneration in Parkinson's disease (PD); however, a link between these features...
15.
Sharma P, Wells L, Rizzo G, Elson J, Passchier J, Rabiner E, et al.
Neurotherapeutics
. 2020 Jan;
17(3):1120-1141.
PMID: 31965550
The brainstem-based pedunculopontine nucleus (PPN) traditionally associates with motor function, but undergoes extensive degeneration during Parkinson's disease (PD), which correlates with axial motor deficits. PPN-deep brain stimulation (DBS) can alleviate...
16.
Gonzalez-Carter D, Goode A, Kiryushko D, Masuda S, Hu S, Lopes-Rodrigues R, et al.
Nanoscale
. 2019 Nov;
11(45):22054-22069.
PMID: 31720664
Nanoparticles capable of penetrating the blood-brain barrier (BBB) will greatly advance the delivery of therapies against brain disorders. Carbon nanotubes hold great potential as delivery vehicles due to their high...
17.
Stephenson D, Hill D, Cedarbaum J, Tome M, Vamvakas S, Romero K, et al.
J Parkinsons Dis
. 2019 Sep;
9(4):825.
PMID: 31524182
No abstract available.
18.
Leo B, Fearn S, Gonzalez-Cater D, Theodorou I, Ruenraroengsak P, Goode A, et al.
Anal Chem
. 2019 Jul;
91(17):11098-11107.
PMID: 31310103
There are no methods sensitive enough to detect enzymes within cells, without the use of analyte labeling. Here we show that it is possible to detect protein ion signals of...
19.
Stephenson D, Hill D, Cedarbaum J, Tome M, Vamvakas S, Romero K, et al.
J Parkinsons Dis
. 2019 Jul;
9(3):553-563.
PMID: 31306141
As therapeutic trials target early stages of Parkinson's disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson's Consortium formally...
20.
Romero K, Conrado D, Burton J, Nicholas T, Sinha V, Macha S, et al.
Clin Transl Sci
. 2019 Feb;
12(3):240-246.
PMID: 30706986
The Critical Path for Parkinson's (CPP) Imaging Biomarker and Modeling and Simulation working groups aimed to achieve qualification opinion by the European Medicines Agency (EMA) Committee for Medical Products for...